EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC

Overview of attention for article published in Journal of Oncology Pharmacy Practice, July 2011

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

patent: 5 patents

Readers on

mendeley: 15 Mendeley

So far, Altmetric has seen 5 patents that reference this research output.

Uracil derivatives as AXL and c-MET kinase inhibitors

Grant US-10017496-B2

United States of America

10 Jul 2018

Uracil derivatives as AXL and c-MET kinase inhibitors

Grant US-9745283-B2

United States of America

29 Aug 2017

Uracil derivatives as AXL and c-MET kinase inhibitors

Grant US-9522902-B2

United States of America

20 Dec 2016

Uracil derivatives as AXL and c-MET kinase inhibitors

Grant US-9120778-B2

United States of America

01 Sep 2015

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 1 additional patents.